SCINAI IMMUNOTHERAPEUTICS LTD. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
SCINAI IMMUNOTHERAPEUTICS LTD. (SCNI) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.20% for the 12-month period ending 2023-12-31, per its 20-F filed 2024-05-15.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2024-05-15
- SCINAI IMMUNOTHERAPEUTICS LTD. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 1.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|
| 2023-12-31 | 4.20% 20-F · filed 2024-05-15 | |
| 2023-03-31 | 1.00% 10-Q · filed 2023-05-15 | |
| 2022-12-31 | 2.10% 20-F · filed 2024-05-15 | |
| 2021-12-31 | 1.70% 20-F · filed 2024-05-15 |